Gabapentin Tablet
Product Images NDC 85534-0010

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 85534-0010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hawaii Repack, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

Line graph depicting mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores on a scale of 0 to 10, with Gabapentin demonstrating a decreasing pain score trend, while placebo remains relatively constant.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over seven weeks during a 3-week dose titration period followed by a 4-week fixed dose period. The graph compares placebo and gabapentin at 1800 mg/day and 2400 mg/day. Gabapentin groups show a decrease in mean pain scores over time compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. The y-axis represents percentage responders from 0% to 100%. Study 1 compares PBO (12%) and GBP 3600 (29%), while Study 2 compares PBO (14%), GBP 1800 (32%), and GBP 2400 (34%). Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

A formula for calculating creatinine clearance (ClCr) based on age, weight, serum creatinine, and a gender correction factor for females. This is a text excerpt likely from a dosage adjustment or pharmacokinetics section related to Gabapentin tablets.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing a cyclohexane ring bonded to functional groups including an amine and a carboxylic acid group, consistent with the generic drug gabapentin.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart depicting the percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis. Data points represent results from three studies labeled a, b, and c, with doses ranging from 600 mg to 1800 mg. Different markers indicate each study's data.*

FDA Label Image

600 (Label 600mg)

This image shows multiple labels for Gabapentin Tablets, USP 600 mg, distributed by Hawaii Repack, Inc. Each label indicates different package quantities: 30, 60, 90, and 120 tablets. Manufactured by ScieGen Pharmaceuticals, Inc., the labels include NDC numbers, storage instructions, and federal caution statements. The tablets are white, film-coated, biconvex, and debossed with 'SG'.*

FDA Label Image

800 (Label 800mg)

Four drug labels for Gabapentin Tablets, USP 800 mg, distributed by Hawaii Repack, Inc., located in Honolulu, HI. Each label shows quantities of 30, 60, 90, and 120 tablets respectively. Manufactured by ScieGen Pharmaceuticals, Inc., the labels include NDC numbers, drug description as white to off-white convex film-coated scored tablets, QR codes, and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.